Apollo Hospitals and Dr Reddy’s Laboratories on Monday said they are collaborating to initiate a COVID-19 vaccination programme with Sputnik V.
The first phase of the programme will kick off with vaccinations in Hyderabad on Monday and in Visakhapatnam on Tuesday (May 18) at Apollo facilities.
The vaccinations would follow the SOPs as recommended by the government including registration on CoWIN.
“This pilot phase will allow Dr. Reddy’s and Apollo to test the arrangements and cold chain logistics and prepare for the launch. We are confident that with the Sputnik V vaccine, we will be able to make a significant contribution to ease availability and access to COVID vaccines to the community at large,” Apollo Hospitals President Hospitals Division K Hari Prasad said in a statement.
With the opening up of the vaccination programme for the private sector, the healthcare major has intensified efforts to accelerate the rate of vaccination through opening vaccination centres across its hospital network, he added.
“We are also in discussions with corporates to undertake vaccination on their premises. We are currently administering COVID vaccine at 60 locations across the country including Apollo Hospitals, Apollo Spectra hospitals and Apollo Clinics,” Prasad said.
Dr Reddy’s Laboratories CEO Branded Markets (India & Emerging Markets) MV Ramana noted that the two entities were working to scale up the pilot and take the vaccine to other cities with an aim to inoculate as many Indians as possible.
The Sputnik V vaccines for the pilot programme would be supplied by Dr Reddy’s from the first batch of 1.5 lakh doses imported so far.
After Hyderabad and Visakhapatnam, the pilot programme will be extended to Delhi, Mumbai, Bengaluru, Ahmedabad, Chennai, Kolkata, and Pune.
In August 2020, Russia became the world’s first country to register a coronavirus vaccine, dubbed as Sputnik V.
Following that, in September, Dr Reddy’s Laboratories and Russian Direct Investment Fund (RDIF) entered into a partnership to conduct clinical trials of Sputnik V, which is developed by the Gamaleya National Research Institute of Epidemiology and Microbiology.
Dr Reddy’s Laboratories has received approval from the Indian drug regulator for restricted emergency use of Sputnik V.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
Source link
